ClinicalTrials.gg
RecruitingNCT06412172Updated Aug 12, 2025

The Natural History and Biological Study of Pulmonary Recurrent Respiratory Papillomatosis (pRRP)

An observational study in Recurrent Respiratory Papillomatosis and Pulmonary Neoplasm, sponsored by Massachusetts General Hospital. Recruiting at 1 site in United States. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2025-08-12.

Sponsored by Massachusetts General Hospital · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Apr 2026, 7 months ago, but the record still lists the study as recruiting.
  • Started Apr 2024; still recruiting 2 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
100
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies in Recurrent respiratory papillomatosis with a site in United States — 8 open to participants now, 9 under way, 1 of them phase 3. Recurrent respiratory papillomatosis · United States.

Started
2024
with 1 other
Observational
4 of 20
2 open now
Registered
15th of 20
by date
Lead sponsor
3 of 20
Massachusetts General Hospital

Among the 20 studies in Recurrent respiratory papillomatosis with a site in United States, this one is one of 2 that started in 2024, is one of 4 observational ones, and was the 15th registered.

Recurrent respiratory papillomatosis

32 studies on the registry are indexed under Recurrent respiratory papillomatosis; 9 are open to participants now.

Browse Recurrent respiratory papillomatosis studies →

Open to participants now

8 of the 20 studies in Recurrent respiratory papillomatosis with a site in United States are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 6 Recurrent respiratory papillomatosis studies recruiting now, 5 set no upper age limit and none stop at 75 or younger; 2 take children under 18; none take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Recurrent respiratory papillomatosis with a site in United States, or all of them as a file.
02

Study summary

Recurrent respiratory papillomatosis (RRP) is an orphan disease that affects approximately 20,000 people in the United States and is caused by infection with human papillomavirus (HPV) types 6 and 11. Since RRP is an orphan disease, it is an understudied disease entity with correspondingly few treatment options. The investigators hypothesize that by understanding the biology of RRP and the failed host immune responses against HPV, novel and rational therapies can be developed. This study will examine the genetic and immunologic alterations found in these rare tumors and distant metastatic involved sites (such as the lung) in patients diagnosed with RRP.

Read the detailed description

Since RRP is an orphan disease, any single institution or hospital treats a limited number of RRP patients. The primary purpose for establishing a tissue repository is to collect RRP tissue from various institutions and hospitals and to provide investigators access to a large number of RRP tissues to perform genetic and immunologic studies of these rare tumors. This is both a prospective and retrospective tissue collection repository. Tissue that will be collected will include excess fresh or archived human tissue, either normal or pathological, that was removed as part of standard of care clinical procedures and/or during procedures performed for separate research purposes, such as a therapeutic clinical trial. Prospectively collected and archived pathology samples will be obtained under informed consent from those patients who are still living. The tissue repository will be de-identified. The PI and the RRP Foundation will collaborate and serve as the gatekeepers of the repository and oversee any tissue requests. Any academic collaborator(s) or for-profit collaborator(s) can request access to the tissue specimens. The investigator or collaborators should submit a letter to express interest in obtaining tissue from the tissue repository to the RRP Foundation and the PI.

03

Conditions studied

  • Recurrent Respiratory Papillomatosis
  • Pulmonary Neoplasm
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients diagnosed with HPV-associated RRP. The investigators will collect, store, and study primary tissue and distant anatomic sites of disease which were removed as part of standard of care.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • History of HPV-associated Recurrent Respiratory Papillomatosis
  • Has pulmonary lesions

Exclusion criteria

Exclusion Criteria:

  • None
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
100 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna
06

What researchers measure

Primary outcomes

  1. Number of Participants with HPV 6 or 11 infection in the pulmonary lesions

    HPV 6 and 11 genotyping will be done via polymerase chain reaction

    Time frame: 24 months

  2. Number of Participants with different mutational profiles in the matched laryngeal and pulmonary lesions

    Sequencing of the HPV genome in the matched laryngeal and pulmonary lesions will be performed.

    Time frame: 24 months

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2024 (actual). Primary completion is estimated for Apr 2026, 23 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 14, 2024
First posted
May 14, 2024
StartActual
Apr 15, 2024
Primary completionEst.
Apr 14, 2026
CompletionEst.
Apr 15, 2030
Last update
Aug 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06412172
Responsible party
Sara Pai, MD, PhD (Associate Surgeon, Massachusetts General Hospital) — Principal investigator
First posted
May 14, 2024
Start date
Apr 15, 2024
Primary completion
Apr 14, 2026 (estimated)
Completion
Apr 15, 2030 (estimated)
Last update
Aug 12, 2025

Study contacts

Sara Pai, MD, PhD
Contact
RRPBiorepository@yale.edu
203-785-5820
Marcelle Stiff
Contact
mstiffpulmonary@rrpf.org
Sara Pai
principal investigator · Yale University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion